The DOI matches its Crossref record; 196 of the 196 references it cites were found in a registry or an index.
Mechanisms of drug combinations: interaction and network perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kawakami, H., Tomita, M., Okudaira, T., Ishikawa, C., Matsuda, T., Tanaka, Y., Nakazato, T., Taira, N., Ohshiro, K., & Mori, N. (2007) · International Journal of Cancer · doi:10.1002/ijc.22403 · Cited by 24
RetractedDatabase resources of the National Center for Biotechnology Information: update
Wheeler, D. L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh073 · Cited by 10,641
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Rhee, I., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,039
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950
(1953) · PubMed · Cited by 942
Microtubules containing acetylated alpha-tubulin in mammalian cells in culture.
Piperno, G., LeDizet, M., & Chang, X. J. (1987) · The Journal of cell biology · doi:10.1083/jcb.104.2.289 · Cited by 873
Nelson, L. E., Lu, J., Guo, T., Saper, C. B., Franks, N. P., & Maze, M. (2003) · Anesthesiology · doi:10.1097/00000542-200302000-00024 · Cited by 854
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Fluorouracil: biochemistry and pharmacology.
Pinedo, H. M., & Peters, G. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1653 · Cited by 834
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Jordan, M. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354290 · Cited by 775
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Oral drug absorption enhancement by chitosan and its derivatives
Thanou, M., Verhoef, J. C., & Junginger, H. E. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00231-9 · Cited by 689
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
Identifying regulatory networks by combinatorial analysis of promoter elements
Pilpel, Y., Sudarsanam, P., & Church, G. M. (2001) · Nature Genetics · doi:10.1038/ng724 · Cited by 652
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
Ghofrani, H. A., Wiedemann, R., Rose, F., Olschewski, H., Schermuly, R. T., Weissmann, N., Seeger, W., & Grimminger, F. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-7-200204020-00008 · Cited by 496
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man
Hinz, B., Cheremina, O., & Brune, K. (2008) · The FASEB Journal · doi:10.1096/fj.07-8506com · Cited by 478
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Smalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463
Verhaar, M. C., Strachan, F. E., Newby, D. E., Cruden, N. L., Koomans, H. A., Rabelink, T. J., & Webb, D. J. (1998) · Circulation · doi:10.1161/01.cir.97.8.752 · Cited by 453
Sintchak, M. D., Fleming, M. A., Futer, O., Raybuck, S. A., Chambers, S. P., Caron, P. R., Murcko, M. A., & Wilson, K. P. (1996) · Cell · doi:10.1016/s0092-8674(00)81275-1 · Cited by 423
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Zhao, W.-H., Hu, Z.-Q., Okubo, S., Hara, Y., & Shimamura, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1737-1742.2001 · Cited by 395
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 386
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
Abal, M., Andreu, J., & Barasoain, I. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481967 · Cited by 383
Structural origins of gentamicin antibiotic action
Yoshizawa, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6437 · Cited by 374
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
Bacus, S. S., Gudkov, A. V., Lowe, M., Lyass, L., Yung, Y., Komarov, A. P., Keyomarsi, K., Yarden, Y., & Seger, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204062 · Cited by 358
Chen, Y. Z., & Zhi, D. G. (2001) · Proteins: Structure, Function, and Genetics · doi:10.1002/1097-0134(20010501)43:2<217::aid-prot1032>3.0.co;2-g · Cited by 353
Self-citationMetabolic network analysis of the causes and evolution of enzyme dispensability in yeast
Papp, B., Pál, C., & Hurst, L. D. (2004) · Nature · doi:10.1038/nature02636 · Cited by 352
Why is cancer drug discovery so difficult?
Kamb, A., Wee, S., & Lengauer, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2155 · Cited by 339
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 325
Physiological significance of α2-adrenergic receptor subtype diversity: one receptor is not enough
Philipp, M., Brede, M., & Hein, L. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2002 · Cited by 318
Lee, J. K., Havaleshko, D. M., Cho, H., Weinstein, J. N., Kaldjian, E. P., Karpovich, J., Grimshaw, A., & Theodorescu, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610292104 · Cited by 316
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Basis for effective combination cancer chemotherapy with antimetabolites
Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00086-3 · Cited by 301
Peng, X.-H., Karna, P., Cao, Z., Jiang, B.-H., Zhou, M., & Yang, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603414200 · Cited by 300
Self-citationAntitumour drugs impede DNA uncoiling by topoisomerase I
Koster, D. A., Palle, K., Bot, E. S. M., Bjornsti, M.-A., & Dekker, N. H. (2007) · Nature · doi:10.1038/nature05938 · Cited by 299
Apoptosome dysfunction in human cancer
Hajra, K. M., & Liu, J. R. (2004) · Apoptosis · doi:10.1023/b:appt.0000045786.98031.1d · Cited by 291
Endothelin receptors and calcium signaling 1
Pollock, D. M., Keith, T. L., & Highsmith, R. F. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.12.7672512 · Cited by 266
Mechanistic Basis of Enzyme-Targeted Drugs
Robertson, J. G. (2005) · Biochemistry · doi:10.1021/bi050247e · Cited by 248
Cui, L., Miao, J., & Cui, L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01238-06 · Cited by 248
Alves, D. S., Pérez-Fons, L., Estepa, A., & Micol, V. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.012 · Cited by 239
Mapping of the Benzodiazepine Recognition Site on GABA-A Receptors
Sigel, E. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393444 · Cited by 225
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
Cheok, M. H., & Evans, W. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1800 · Cited by 217
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells
Faivre, S., Chan, D., Salinas, R., Woynarowska, B., & Woynarowski, J. M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00260-0 · Cited by 211
Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action
Narishetty, S. T. K., & Panchagnula, R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.11.022 · Cited by 207
Antifungal agents: mode of action in yeast cells.
Carrillo‐Muñoz, A. J., Giusiano, G., Ezkurra, P. A., & Quindós, G. (2006) · PubMed · Cited by 203
p38 MAP kinase mediates stress‐induced internalization of EGFR: implications for cancer chemotherapy
Zwang, Y., & Yarden, Y. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601297 · Cited by 202
Bridging Chemical and Biological Space: “Target Fishing” Using 2D and 3D Molecular Descriptors
Nettles, J. H., Jenkins, J. L., Bender, A., Deng, Z., Davies, J. W., & Glick, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060902w · Cited by 201
5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction
Sun, X.-X., Dai, M.-S., & Lu, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610621200 · Cited by 199
Taxol Induces Caspase-10-dependent Apoptosis
Park, S.-J., Wu, C.-H., Gordon, J. D., Zhong, X., Emami, A., & Safa, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406543200 · Cited by 198
Mode of action and in-vitro activity of vancomycin
Watanakunakorn, C. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.7 · Cited by 197
Cell wall integrity modulates RHO1 activity via the exchange factor ROM2
Bickle, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2235 · Cited by 192
Niacin and cholesterol: role in cardiovascular disease (review)
Ganji, S. H., Kamanna, V. S., & Kashyap, M. L. (2003) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00284-x · Cited by 189
Emodin, a Protein Tyrosine Kinase Inhibitor from Polygonum cuspidatum
Jayasuriya, H., Koonchanok, N. M., Geahlen, R. L., McLaughlin, J. L., & Chang, C.-J. (1992) · Journal of Natural Products · doi:10.1021/np50083a026 · Cited by 185
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
Self-citationGajate, C., & Mollinedo, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411781200 · Cited by 184
Evidence of involvement of central neural mechanisms in generating fibromyalgia pain
Staud, R. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0038-5 · Cited by 183
Curcumin-Artemisinin Combination Therapy for Malaria
Nandakumar, D. N., Nagaraj, V. A., Vathsala, P. G., Rangarajan, P., & Padmanaban, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1859-1860.2006 · Cited by 183
Mechanism of Acetaminophen Inhibition of Cyclooxygenase Isoforms
Ouellet, M., & Percival, M. D. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2232 · Cited by 166
De Clercq, E. (1993) · Medicinal Research Reviews · doi:10.1002/med.2610130303 · Cited by 166
New targets and delivery systems for antifungal therapy
Walsh, T. J., Viviani, M.-A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A. H., & Odds, F. C. (2000) · Medical Mycology · doi:10.1080/mmy.38.s1.335.347 · Cited by 161
Massarweh, S., & Schiff, R. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01273 · Cited by 159
β-lactams against methicillin-resistant
Guignard, B., Entenza, J. M., & Moreillon, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.002 · Cited by 149
Normanno, N., Luca, A. D., Maiello, M. R., Campiglio, M., Napolitano, M., Mancino, M., Carotenuto, A., Viglietto, G., & Ménard, S. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20588 · Cited by 145
Better therapeutics through microarrays
Gerhold, D. L., Jensen, R. V., & Gullans, S. R. (2002) · Nature Genetics · doi:10.1038/ng1042 · Cited by 141
Towards a mechanism-based analysis of pharmacodynamic drug?drug interactions in vivo
Jonker, D. M., Visser, S. A. G., VANDERGRAAF, P., Voskuyl, R. A., & Danhof, M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.014 · Cited by 134
Interactions between drugs and occupied receptors
Tallarida, R. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.002 · Cited by 130
Signal Transduction Pathways of Taxanes-Induced Apoptosis
Ganansia, V., Bischoff, P. L., Bergerat, J., et al. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033482422 · Cited by 128
Narishetty, S. T. K., & Panchagnula, R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.016 · Cited by 127
Antimalarial drug synergism and antagonism: Mechanistic and clinical significance
Bell, A. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2005.09.035 · Cited by 124
Azithromycin—Spectrum of Activity, Pharmacokinetics, and Clinical Applications
Drew, R. H., & Gallis, H. A. (1992) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1992.tb04504.x · Cited by 122
The Actions of Sevoflurane and Desflurane on the γ-Aminobutyric Acid Receptor Type A
Nishikawa, K., & Harrison, N. L. (2003) · Anesthesiology · doi:10.1097/00000542-200309000-00024 · Cited by 120
Brogden, R. N., Carmine, A., Heel, R. C., et al. (1981) · Drugs · doi:10.2165/00003495-198122050-00001 · Cited by 116
Illuminating drug discovery with biological pathways
Apic, G., Ignjatovic, T., Boyer, S. K., & Russell, R. B. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.023 · Cited by 116
Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquières, G., Jaehde, U., Kassack, M. U., Gazdar, A. F., Minna, J. D., & Royer, H. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706287200 · Cited by 115
Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci
Rand, K. H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh104 · Cited by 114
Koizumi, F., Kanzawa, F., Ueda, Y., Koh, Y., Tsukiyama, S., Taguchi, F., Tamura, T., Saijo, N., & Nishio, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11539 · Cited by 113
Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance
Krishna, S., Woodrow, C. J., Staines, H. M., Haynes, R. K., & Mercereau‐Puijalon, O. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.03.005 · Cited by 111
Meletiadis, J., Petraitis, V., Petraitienė, R., Lin, P., Stergiopoulou, T., Kelaher, A. M., Sein, T., Schaufele, R. L., Bacher, J. D., & Walsh, T. J. (2006) · The Journal of Infectious Diseases · doi:10.1086/506617 · Cited by 111
Lee, S., Yang, W., Lan, K., Sellappan, S., Klos, K. S., Hortobágyi, G. N., Hung, M., & Yu, D. (2002) · PubMed · Cited by 109
Recovering the true targets of specific ligands by virtual screening of the protein data bank
Paul, N., Kellenberger, E., Bret, G., Müller, P., & Rognan, D. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10625 · Cited by 109
Marcus, A. I., Zhou, J., O’Brate, A., Hamel, E., Wong, J. Y. Y., Nivens, M. C., El‐Naggar, A. K., Yao, T., Khuri, F. R., & Giannakakou, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3757 · Cited by 109
Baruah, H., Barry, C. G., & Bierbach, U. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387313 · Cited by 108
Targeted Deletion of mNth1 Reveals a Novel DNA Repair Enzyme Activity
Ocampo, M. A., Chaung, W., Marenstein, D. R., Chan, M. K., Altamirano, A. M., Basu, A. K., Boorstein, R. J., Cunningham, R. P., & Teebor, G. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6111-6121.2002 · Cited by 106
Robust Ligand-Based Modeling of the Biological Targets of Known Drugs
Cleves, A. E., & Jain, A. N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051139t · Cited by 104
Antifúngicos: mecanismo de acción en células de levaduras
Quindós, G., Giusiano, G., Ezkurra, P. A., & Muñoz, A. J. C. (2006) · Revista española de quimioterapia. Suplemento · Cited by 102
Plosker, G. L., & McTavish, D. (1995) · Drugs · doi:10.2165/00003495-199550020-00009 · Cited by 102
Honoré, S., Kamath, K., Braguer, D., Horwitz, S. B., Wilson, L., Briand, C. M., & Jordan, M. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0693 · Cited by 100
Protein interactions with platinum–DNA adducts: from structure to function
Chaney, S. G., Campbell, S. L., Temple, B. R. S., Bassett, E., Wu, Y., & Faldu, M. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.024 · Cited by 99
Tham, S. M., Angus, J. A., Tudor, E. M., & Wright, C. E. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706045 · Cited by 98
Advancing drug discovery through systems biology
Davidov, E., Holland, J., Marple, E. W., & Naylor, S. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02600-x · Cited by 98
Mechanisms of Resistance to Imipenem and Ampicillin in Enterococcus faecalis
Ono, S., Muratani, T., & Matsumoto, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2954-2958.2005 · Cited by 96
Madiraju, C., Edler, M., Hamel, E., Raccor, B. S., Balachandran, R., Zhu, G., Giuliano, K. A., Vogt, A., Shin, Y., Fournier, J., et al. (2005) · Biochemistry · doi:10.1021/bi050685l · Cited by 95
Kassouf, W., Dinney, C. P., Brown, G. A., McConkey, D. J., Diehl, J. A., Bar‐Eli, M., & Adam, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1536 · Cited by 92
Curatolo, M., & Sveticic, G. (2002) · Best practice & research. Clinical anaesthesiology · doi:10.1053/bean.2002.0254 · Cited by 91
The combination of yondelis and cisplatin is synergistic against human tumor xenografts
D’Incalci, M., Colombo, T., Ubezio, P., Nicoletti, I., Giavazzi, R., Erba, E., Ferrarese, L., Meco, D., Riccardi, R., Sessa, C., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00490-8 · Cited by 90
Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in human brain
Boulenger, J., Patel, J. B., & Marangos, P. J. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90290-7 · Cited by 89
Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma
Nelson, H. S. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112939 · Cited by 88
Rickardson, L., Fryknäs, M., Dhar, S., Lövborg, H., Gullbo, J., Rydåker, M., Nygren, P., Gustafsson, M. G., Larsson, R., & Isaksson, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602699 · Cited by 82
Schwieler, L., Erhardt, S., Erhardt, C., & Engberg, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0231-y · Cited by 81
Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone
Zhang, X., Moilanen, E., & Kankaanranta, H. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00690-7 · Cited by 80
Soares, A. C., & Duarte, I. D. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704224 · Cited by 80
Zewail‐Foote, M., LI, V. ‐., Kohn, H., Bearss, D. J., Guzman, M., & Hurley, L. H. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00071-0 · Cited by 79
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77
Meekins, C. V., Sullivan, T. J., & Gruchalla, R. S. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(94)90120-1 · Cited by 76
Touma, S. E., Goldberg, J. S., Moench, P. A., Guo, X., Tickoo, S. K., Gudas, L. J., & Nanus, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1155 · Cited by 76
Yao, Q., Weigel, B. J., & Kersey, J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1750 · Cited by 75
Cegelski, L., Kim, S. J., Hing, A. W., Studelska, D. R., O'Connor, R. D., Mehta, A. K., & Schaefer, J. (2002) · Biochemistry · doi:10.1021/bi0202326 · Cited by 75
Han, L., Zheng, C., Xie, B., Jia, J., Xiao, H., Zhu, F., Lin, H., Chen, X., & Chen, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.015 · Cited by 74
Self-citationFletcher, D., Benoist, J. M., Gautron, M., & Guilbaud, G. (1997) · Anesthesiology · doi:10.1097/00000542-199708000-00019 · Cited by 72
Pennati, M., Campbell, A. J., Curto, M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0022 · Cited by 72
Le, X., Lammayot, A., Gold, D. L., Lu, Y., Mao, W., Chang, T., Patel, A. M., Mills, G. B., & Bast, R. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403080200 · Cited by 71
Fernandes, D., & Bertino, J. R. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.5663 · Cited by 70
Villalón, C. M., de Vries, P. W., Rabelo, G., Centurión, D., Sánchez‐López, A., & Saxena, P. R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702324 · Cited by 69
Chemotherapy in non-small cell lung cancer: results of recent trials.
Loehrer, P. J., Einhorn, L. H., & Fa, G. (1988) · PubMed · Cited by 67
Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules
Bella, S. D., Molteni, M., Mocellin, C., Fumagalli, S., Bonara, P., & Scorza, R. (2001) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(01)00131-9 · Cited by 66
JNK activation is critical for Aplidin™-induced apoptosis
Cuadrado, A., González, L., Suárez, Y., Martínez, T., & Múñoz, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207636 · Cited by 66
Pathway Analysis Tools and Toxicogenomics Reference Databases for Risk Assessment
Ganter, B., Zidek, N., Hewitt, P., Müller, D., & Vladimirova, A. (2007) · Pharmacogenomics · doi:10.2217/14622416.9.1.35 · Cited by 66
Alkylation of guanosine and deoxyguanosine by phosphoramide mustard.
Mehta, J. R., Przybylski, M., & Ludlum, D. B. (1980) · PubMed · Cited by 63
Graham, B. A., Hammond, D. L., & Proudfit, H. K. (2000) · Pain · doi:10.1016/s0304-3959(99)00261-4 · Cited by 62
Zhang, W., Lee, J. C., Kumar, S., & Gowen, M. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.528 · Cited by 61
Meltzer, E. O. (1997) · Allergy · doi:10.1111/j.1398-9995.1997.tb04820.x · Cited by 60
Goddard, J. G., Eckhart, C., Johnston, N. R., Cumming, A. D., Rankin, A. J., & Webb, D. J. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000141313.84470.4b · Cited by 58
Rational drug discovery: what can we learn from regulatory networks?
Huang, S. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02463-7 · Cited by 57
Kim, H. S., & Fay, J. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708194104 · Cited by 57
Emerging applications of network and pathway analysis in drug discovery and development.
Ganter, B., & Giroux, C. N. (2008) · PubMed · Cited by 57
Stein, E. A., Davidson, M. H., Dujovne, C. A., Hunninghake, D. B., Goldberg, R. B., Illingworth, D. R., Knopp, R. H., Miller, V. T., Frost, P., Isaacsohn, J. L., et al. (1996) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849600100204 · Cited by 56
Olsen, B. B., Bjørling-Poulsen, M., & Guerra, B. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.08.006 · Cited by 54
Pace, E., Gagliardo, R. P., Melis, M. R., Grutta, S. L., Ferraro, M., Siena, L., Bonsignore, G., Gjomarkaj, M., Bousquet, J. J., & Vignola, A. M. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.052 · Cited by 53
Crosstalk of oncogenic and prostanoid signaling pathways
M�ller, R. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0570-y · Cited by 51
Harris, R. S., Lazar, O., Johansen, J. W., & Sebel, P. S. (2006) · Anesthesiology · doi:10.1097/00000542-200606000-00011 · Cited by 47
Gupta, E. K., & Ito, M. K. (2002) · Heart Disease · doi:10.1097/00132580-200203000-00010 · Cited by 47
Ciccolini, J., Peillard, L., Evrard, A., Cuq, P., Aubert, C., Pèlegrin, A., Formento, P., Milano, G. A., & Catalin, J. (2000) · PubMed · Cited by 46
Matsuura, M., Nakazawa, H., Hashimoto, T., & Mitsuhashi, S. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.6.908 · Cited by 46
Antimicrobial synergy between mRNA- and protein-level inhibitors
Dryselius, R., Nekhotiaeva, N., & Good, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki173 · Cited by 45
Pelicano, H., Carew, J. S., McQueen, T. J., Andreeff, M., Plunkett, W. K., Keating, M. J., & Huang, P. C. (2006) · Leukemia · doi:10.1038/sj.leu.2404140 · Cited by 44
Grimaldi, K. A., McAdam, S. R., Souhami, R. L., & Hartley, J. A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.12.2311 · Cited by 44
Principles: Mechanisms and modeling of synergism in cellular responses
Barrera, N. P., Morales, B., Torres, S., & Villalón, M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.003 · Cited by 44
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage
Nishikawa, K. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000634 · Cited by 43
Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.
Greenwood, D. R., & O'Grady, F. (1976) · Journal of Clinical Pathology · doi:10.1136/jcp.29.2.162 · Cited by 43
Nonlinear Blending: A Useful General Concept for the Assessment of Combination Drug Synergy
Peterson, J. J., & Novick, S. J. (2007) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890701417576 · Cited by 40
Moridaira, K., Morrissey, J. J., Fitzgerald, M., Guo, G., McCracken, R., Tolley, T., & Klahr, S. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00352.2001 · Cited by 38
Desensitization of NO/cGMP Signaling in Smooth Muscle: Blood Vessels Versus Airways
Müllershausen, F., Lange, A., Mergia, E., Friebe, A., & Koesling, D. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020909 · Cited by 37
Anaesthetic binding sites for etomidate and propofol on a GABAA receptor model
Campágna‐Slater, V., & Weaver, D. F. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.02.091 · Cited by 36
Georgakis, G. V., Li, Y., Rassidakis, G. Z., Medeiros, L. J., & Younes, A. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.07.002 · Cited by 36
Self-citationFunakoshi, M., Tago, K., Sonoda, Y., Tominaga, S., & Kasahara, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4759 · Cited by 36
Spontaneous Spike Activity of Spinoreticular Tract Neurons During Sleep and Wakefulness
Soja, P. J., Pang, W., Taepavarapruk, N., & McErlane, S. A. (2001) · SLEEP · doi:10.1093/sleep/24.1.18 · Cited by 35
Menez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P. M., & BARRATT, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00837-06 · Cited by 34
Dinos, G. P., Connell, S. R., Nierhaus, K. H., & Kalpaxis, D. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.617 · Cited by 33
André, F., Mazouni, C., Hortobágyi, G. N., & Pusztai, L. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.002 · Cited by 31
From drug to protein: using yeast genetics for high-throughput target discovery
Armour, C. D., & Lum, P. Y. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.12.001 · Cited by 29
Okano, J., Nagahara, T., Matsumoto, K., & Murawaki, Y. (2007) · Oncology Reports · doi:10.3892/or.17.5.1195 · Cited by 29
Demonstration of Distinct Agonist and Antagonist Conformations of the A1 Adenosine Receptor
Barrington, W. W., Jacobson, K. A., & Stiles, G. L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51609-4 · Cited by 28
Voeller, D. M., Kovacs, J. A., Andrawis, V. A., Chu, E., Masur, H., & Allegra, C. J. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.456 · Cited by 27
Rigourd, M., Ehresmann, C., Parniak, M. A., Ehresmann, B., & Marquet, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110836200 · Cited by 26
Ara-C affects formation of cancer cell DNA synthesome replication intermediates
Abdel‐Aziz, W., Jiang, H., Hickey, R. J., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050046 · Cited by 25
Zanchi, C., Zuco, V., Lanzi, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2495 · Cited by 24
Pathway Analysis for Design of Promiscuous Drugs and Selective Drug Mixtures
Sivachenko, A., Калинин, А. А., & Yuryev, A. (2006) · Current Drug Discovery Technologies · doi:10.2174/157016306780368117 · Cited by 23
Cruchaga, C., Odriozola, L., Andréola, M., Tarrago‐Litvak, L., & Martínez-Irujo, J. J. (2005) · Biochemistry · doi:10.1021/bi048129z · Cited by 23
Binding and effect of KATP channel openers in the absence of Mg2+
Ruß, U., Lange, U., Löffler‐Walz, C., Hambrock, A., & Quast, U. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705238 · Cited by 23
de Carvalho-Netto, E. F., Markham, C. M., Blanchard, D. C., Nunes‐de‐Souza, R. L., & Blanchard, R. J. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.022 · Cited by 20
Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro
Tanaka, R., Ariyama, H., Qin, B., Shibata, Y., Takii, Y., Kusaba, H., Baba, E., Mitsugi, K., Harada, M., & Nakano, S. (2005) · Oncology Reports · doi:10.3892/or.14.3.683 · Cited by 17
Biebricher, C. Κ., & Druminski, M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.2.866 · Cited by 17
Marco, E., & Gago, F. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015685 · Cited by 17
Trimetrexate: experience with solid tumors.
Haller, D. G. (1997) · PubMed · Cited by 15
Biochemistry and Action of Clavulanic Acid
Cole, M. (1982) · Scottish Medical Journal · doi:10.1177/00369330820270s103 · Cited by 13
Wirth, G. J., Schandelmaier, K., Smith, V., Burger, A. M., & Fiebig, H. (2006) · Oncology · doi:10.1159/000100476 · Cited by 13
Xiong, H., & Choe, Y. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-9 · Cited by 11
Rojo, F., Ayala, J. A., de Pedro, M. A., & VAZQUEZ, D. (1984) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1984.tb08503.x · Cited by 10
SV40 DNA Replication Inhibition by the Monofunctional DNA Alkylator Et743
Dziegielewska, B., Kowalski, D., & Beerman, T. A. (2004) · Biochemistry · doi:10.1021/bi049407x · Cited by 10
Mondimore, F. M., Fuller, G. A., & DePaulo, J. R. (2003) · PubMed · Cited by 9
The development of combination drugs for atherosclerosis
Black, D. M. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0065-3 · Cited by 7
Internet Resources Related to Drug Action and Human Response: A Review
Yao, L. X., Wu, Z., Ji, Z., Chen, Y., & Chen, X. (2006) · Applied Bioinformatics · doi:10.2165/00822942-200605030-00001 · Cited by 6
Self-citationRamipril in the treatment of vascular diseases
Rokoss, M. J., & Teo, K. K. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.11.1911 · Cited by 5
Nelson, H. S. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.114048 · Cited by 4
Cited by
Modeling polypharmacy side effects with graph convolutional networks
Zitnik, M., Agrawal, M., & Leskovec, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty294 · Cited by 1,501
Traditional Chinese medicine network pharmacology: theory, methodology and application
LI, S., & ZHANG, B. (2013) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(13)60037-0 · Cited by 1,329
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Metadata
- Authors
- Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-02
- Volume
- 8
- Issue
- 2
- Pages
- 111-128
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2061136308
- Cited by
- 969
- References
- 196
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.